Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eNK:IO cells
- Development stage
- Preclinical
- Lead developer
- NK:IO
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intratumoral, Intraperitoneal
01
Overview
eNK:IO cells are a next-generation engineered natural killer (NK) cell therapy developed by NK:IO for cancer immunotherapy. These human NK cells are produced by deleting specific inhibitory receptors on the cell surface prior to differentiation into mature NK cells, resulting in "super" NK cells with enhanced cytotoxicity and tumor-sensing properties. The approach aims to overcome the exhaustion phenotype seen in other NK cell therapies and improve anti-tumor efficacy, particularly for hard-to-treat solid tumors such as ovarian cancer. The technology leverages umbilical cord blood-derived stem/progenitor cells and proprietary expansion methods to generate highly functional therapeutic products[1][2].
- Other names
- eNKIOengineered NK:IO cellsengineered NK cells (from NK:IO)
02
Targets
LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on eNK:IO cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eNK:IO cells.